Find Clopidogrel Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 120202-65-5, 426o7xws6y, Clopidogrel (tn), Unii-426o7xws6y, Clopidogrel hcl, Clopidogrel-hcs
Molecular Formula
C16H17Cl2NO2S
Molecular Weight
358.3  g/mol
InChI Key
XIHVAFJSGWDBGA-RSAXXLAASA-N
FDA UNII
426O7XWS6Y

Clopidogrel Hydrochloride
A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.
1 2D Structure

Clopidogrel Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate;hydrochloride
2.1.2 InChI
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1
2.1.3 InChI Key
XIHVAFJSGWDBGA-RSAXXLAASA-N
2.1.4 Canonical SMILES
COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.Cl
2.1.5 Isomeric SMILES
COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3.Cl
2.2 Other Identifiers
2.2.1 UNII
426O7XWS6Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Clopidogrel

2. Clopidogrel Besilate

3. Clopidogrel Besylate

4. Clopidogrel Bisulfate

5. Clopidogrel Mepha

6. Clopidogrel Napadisilate

7. Clopidogrel Sandoz

8. Clopidogrel, (+)(s)-isomer

9. Clopidogrel-mepha

10. Iscover

11. Pcr 4099

12. Pcr-4099

13. Plavix

14. Sc 25989c

15. Sc 25990c

16. Sr 25989

2.3.2 Depositor-Supplied Synonyms

1. 120202-65-5

2. 426o7xws6y

3. Clopidogrel (tn)

4. Unii-426o7xws6y

5. Clopidogrel Hcl

6. Clopidogrel-hcs

7. Clopidogrel-tad

8. Clopidogrel-dura

9. Clopidogrel-hydrochlorid

10. Clopidogrel-krka

11. Clopidogrel Mylan

12. Clopidogrel Qualimed

13. Clopidogrel Teva Pharma

14. Schembl1031047

15. Dtxsid40152734

16. Clopidogrel Teva Generics B.v.

17. Clopidogrel Hydrochloride [who-dd]

18. Clopidogrel Hydrochloride [ema Epar]

19. Cs-0165212

20. Clopidogrel Hydrochloride [ep Monograph]

21. D10823

22. Q27258500

23. (s)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4h)-yl)acetate Hydrochloride? (clopidogrel Impurity Pound(c)

24. Methyl (2s)-2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate;hydrochloride

25. Methyl-(s)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridine-5-yl)-acetate Hydrochloride

26. Thieno(3,2-c)pyridine-5(4h)-acetic Acid, .alpha.-(2-chlorophenyl)-6,7-dihydro-, Methyl Ester, Hydrochloride, (s)-

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 358.3 g/mol
Molecular Formula C16H17Cl2NO2S
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
Exact Mass357.0357053 g/mol
Monoisotopic Mass357.0357053 g/mol
Topological Polar Surface Area57.8 Ų
Heavy Atom Count22
Formal Charge0
Complexity381
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

Secondary prevention of atherothrombotic events

Clopidogrel is indicated in:

- Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

- Adult patients suffering from acute coronary syndrome:

- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).

- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

In patients with moderate to high-risk Transient Ischaemic Attack (TIA) or minor Ischaemic Stroke (IS)

Clopidogrel in combination with ASA is indicated in:

- Adult patients with moderate to high-risk TIA (ABCD2 score 4) or minor IS (NIHSS 3) within 24 hours of either the TIA or IS event.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

For further information please refer to section 5. 1.


Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

For further information please refer to section 5. 1.


Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

- Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

- Patients suffering from acute coronary syndrome:

- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).

- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

For further information please refer to section 5. 1.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Purinergic P2Y Receptor Antagonists

Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes. (See all compounds classified as Purinergic P2Y Receptor Antagonists.)


Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


5.2 ATC Code

B01AC04


B01AC06


B01AC04


REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Clopidogrel Hydrochloride Manufacturers

A Clopidogrel Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Clopidogrel Hydrochloride, including repackagers and relabelers. The FDA regulates Clopidogrel Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Clopidogrel Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Clopidogrel Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Clopidogrel Hydrochloride Suppliers

A Clopidogrel Hydrochloride supplier is an individual or a company that provides Clopidogrel Hydrochloride active pharmaceutical ingredient (API) or Clopidogrel Hydrochloride finished formulations upon request. The Clopidogrel Hydrochloride suppliers may include Clopidogrel Hydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Clopidogrel Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Clopidogrel Hydrochloride CEP

A Clopidogrel Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Clopidogrel Hydrochloride Certificate of Suitability (COS). The purpose of a Clopidogrel Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Clopidogrel Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Clopidogrel Hydrochloride to their clients by showing that a Clopidogrel Hydrochloride CEP has been issued for it. The manufacturer submits a Clopidogrel Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Clopidogrel Hydrochloride CEP holder for the record. Additionally, the data presented in the Clopidogrel Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Clopidogrel Hydrochloride DMF.

A Clopidogrel Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Clopidogrel Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Clopidogrel Hydrochloride suppliers with CEP (COS) on PharmaCompass.

Clopidogrel Hydrochloride WC

A Clopidogrel Hydrochloride written confirmation (Clopidogrel Hydrochloride WC) is an official document issued by a regulatory agency to a Clopidogrel Hydrochloride manufacturer, verifying that the manufacturing facility of a Clopidogrel Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Clopidogrel Hydrochloride APIs or Clopidogrel Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Clopidogrel Hydrochloride WC (written confirmation) as part of the regulatory process.

click here to find a list of Clopidogrel Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.

Clopidogrel Hydrochloride GMP

Clopidogrel Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Clopidogrel Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Clopidogrel Hydrochloride GMP manufacturer or Clopidogrel Hydrochloride GMP API supplier for your needs.

Clopidogrel Hydrochloride CoA

A Clopidogrel Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Clopidogrel Hydrochloride's compliance with Clopidogrel Hydrochloride specifications and serves as a tool for batch-level quality control.

Clopidogrel Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Clopidogrel Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Clopidogrel Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Clopidogrel Hydrochloride EP), Clopidogrel Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Clopidogrel Hydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty